Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment

Summary

Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinson's Disease patients with the pathogenic mutation of LRRK2, in October of 2022.

The company initiated a phase 2b study, using BIIB122 for the treatment of early-stage Parkinson's Disease patients, in May of 2022.

Both studies using BIIB122 for the treatment of patients with Parkinson's Disease are being done in collaboration with Biogen.

It is expected that the global Parkinson's Disease Market will reach a value of $6.70 billion by 2030

seekingalpha.com/article/45...

[jeffmayer]

what is classed as early stage